We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Global Microfluidic Immunoassay Market to Reach USD 2 Billion by 2025

By LabMedica International staff writers
Posted on 01 Oct 2019
The global microfluidic immunoassay market is expected to grow at a CAGR of 12.7% from 2019 to USD 2.0 billion by 2025, driven by greater benefits offered by Lab-on-chip (LOC) over conventional quantifiable technologies, the growing need for point-of-care (POC) in low-resource settings, and increasing research activities in the field of microfluidic technology. More...
The market growth will be further aided by increased venture capital funding for the development of LOC-based POC diagnostics, rapid decision-making in emergency care, and rising incidence and prevalence of chronic diseases coupled with an aging population.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Additionally, the emerging economies and novel technologies, such as paper-based microfluidics, will also provide significant growth opportunities for the market players. However, the lengthy approval time for POC devices and reluctance among healthcare professionals to replace existing diagnostic platforms are likely to hinder market growth. Nevertheless, the selection of suitable substrate material for designing microfluidic chip, difficulty in up-scaling the process for mass production, and product-design and cost-related challenges in the developing countries will prove to be the major hurdles for market growth.

Based on product type, the adoption of LOC/microfluidic diagnostics is expected to grow at the fastest CAGR in 2019 owing to its capability for scaling down whole laboratory processes on a single chip and expediting the process of disease diagnosis with highly precise quantitative results. On the basis of technology, the non-LOC POC technologies segment is estimated to hold the largest share of the global microfluidic immunoassay market in 2019 due to increased adoption of these technologies over the years for a wide range of diagnostic applications. However, LOC POC technology is expected to grow at the fastest CAGR during the forecast period, mainly due to greater benefits offered by LOC over conventional POC diagnostic methods and growing research activities in this field that are supported by private and public funding.

Based on application, the cardiac biomarker detection segment is estimated to hold the largest share of the global microfluidic immunoassay market in 2019 and also grow at the fastest CAGR during the forecast period. The segment’s performance is expected to be driven by the high prevalence of cardiovascular diseases, availability of a large number of LOC-based products for cardiac biomarkers, and greater adoption of these products by end-users. Geographically, North America is expected to hold the largest share of the global microfluidic immunoassay market in 2019, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Related Links:
Research and Markets


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Plasmodium Test
Plasmodium DNA Real Time PCR Kit
New
Glucose Tolerance Test
NERL Trutol
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.